IPI was founded in 2017 by scientists Tim Springer and Andrew Kruse of Harvard Medical School.
The Institute is headquartered on the Harvard Medical School campus in Boston’s Longwood Medical and Academic Area.
IPI is making synthetic recombinant antibodies and distributing them to scientists through its nonprofit partner Addgene.
IPI is financially secured by substantial gifts from co-founder Tim Springer, revenue from antibody distribution, sponsored research and federal funding.
IPI employs approximately 40 people, mostly scientists and research associates staffing its antibody platform.
IPI is a nonprofit 501(c)3 organization.
IPI’s mission is to accelerate research and improve human health by providing scientists with openly shared protein tools capable of illuminating fundamental biological processes.
At IPI’s core is a scientific platform matching rare, state-of-the-art technology with skilled scientists from top institutions around the world.
Our scientists apply their protein expertise to scalable, multidisciplinary projects that focus on the basic molecular processes that drive human biology, especially in neurobiology, immunology and cancer.